Related Experiment Video
Updated: Jul 2, 2025

Visualization of DNA Repair Proteins Interaction by Immunofluorescence
Published on: June 26, 2020
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair
Yumin Wang1, Boya Gao1,2, Luyuan Zhang3
1Massachusetts General Hospital Cancer Center, Harvard Medical School, 13th Street, Charlestown, MA, 02129, USA.
Abstract:
Drugs targeting the DNA damage response (DDR) are widely used in cancer therapy, but resistance to these drugs remains a major clinical challenge. Here, we show that SYCP2, a meiotic protein in the synaptonemal complex, is aberrantly and commonly expressed in breast and ovarian cancers and associated with broad resistance to DDR drugs. Mechanistically, SYCP2 enhances the repair of DNA double-strand breaks (DSBs) through transcription-coupled homologous recombination (TC-HR). SYCP2 promotes R-loop formation at DSBs and facilitates RAD51 recruitment independently of BRCA1. SYCP2 loss impairs RAD51 localization, reduces TC-HR, and renders tumors sensitive to PARP and topoisomerase I (TOP1) inhibitors. Furthermore, our studies of two clinical cohorts find that SYCP2 overexpression correlates with breast cancer resistance to antibody-conjugated TOP1 inhibitor and ovarian cancer resistance to platinum treatment. Collectively, our data suggest that SYCP2 confers cancer cell resistance to DNA-damaging agents by stimulating R-loop-mediated DSB repair, offering opportunities to improve DDR therapy.
Insights
A meiotic protein, SYCP2, is overexpressed in breast and ovarian cancers, driving resistance to DNA damage response (DDR) drugs by enhancing DNA repair. Targeting SYCP2 may improve cancer therapy outcomes.
Area of Science:
- Molecular Biology
- Cancer Research
- Genetics
Background:
- DNA damage response (DDR) drugs are crucial in cancer therapy, but drug resistance is a significant clinical hurdle.
- Aberrant protein expression can drive therapeutic resistance in various cancers.
Purpose of the Study:
- To investigate the role of SYCP2, a meiotic protein, in cancer and its association with resistance to DDR drugs.
- To elucidate the mechanism by which SYCP2 influences DNA repair and drug sensitivity.
Main Methods:
- Analysis of SYCP2 expression in breast and ovarian cancer patient cohorts.
- Investigating SYCP2's role in DNA double-strand break (DSB) repair pathways, including transcription-coupled homologous recombination (TC-HR).
- Assessing the impact of SYCP2 on RAD51 recruitment and R-loop formation at DSBs.
- Evaluating the sensitivity of tumors with varying SYCP2 levels to PARP inhibitors, topoisomerase I (TOP1) inhibitors, and platinum-based chemotherapy.
Main Results:
- SYCP2 is aberrantly expressed in breast and ovarian cancers and linked to broad resistance to DDR drugs.
- SYCP2 enhances DSB repair via transcription-coupled homologous recombination (TC-HR) by promoting R-loop formation and RAD51 recruitment, independent of BRCA1.
- SYCP2 loss sensitizes tumors to PARP and TOP1 inhibitors.
- Clinical data show SYCP2 overexpression correlates with resistance to TOP1 inhibitors in breast cancer and platinum treatment in ovarian cancer.
Conclusions:
- SYCP2 promotes cancer cell resistance to DNA-damaging agents by enhancing R-loop-mediated DSB repair.
- Targeting SYCP2 presents a potential strategy to overcome DDR drug resistance in cancer therapy.
More Related Videos
Related Concept Videos
DNA Damage can Stall the Cell Cycle
Restarting Stalled Replication Forks
Single-Strand DNA Binding Proteins
Negative Regulator Molecules
Homologous Recombination
Translesion DNA Polymerases
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...

